Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
(1d)
China’s Henlius carves out $440M T-cell engager deal with Amberstone
(1d)
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
(1d)
Merck sees pivotal victory for $3B eye disease prospect
(1d)
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
(1d)
BioPharma Dive
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
(7h)
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
(10h)
RNAi drug specialist ADARx raises $446M IPO
(23h)
Grail multicancer detection test wins FDA advisers’ backing
(1d)
FDA nominee Overton parries vaccine questions at Senate hearing
(1d)
Endpoints News
FDA approves Mirum’s drug for ultra-rare soft tissue disease
(4h)
Jury awards Nektar $90M in suit against Lilly
(6h)
Pharma industry asks FDA for more details on when one trial is enough
(7h)
To get drugmakers into ultra-rare disease, the answer isn’t rare disease at all
(8h)
Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
(9h)
BioSpace
After COVID, biomanufacturing tackles preparedness and commercialization challenges
(9h)
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
(9h)
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
(10h)
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
(10h)
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
(11h)
STAT News
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
(6h)
Lilly wins approval for once-weekly insulin shot
(8h)
FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
(9h)
Up and down the ladder: The latest comings and goings
(10h)
We’re reading about a reticent FDA commish nominee, a Novo deal, and more
(10h)
BioPharma Trend
AI Drug Discovery Startups Raise $526 Million in Two Days
(1d)
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?
(4d)
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?
(5d)
Is “Rescuing Failed Drugs with AI” a Category Now?
(5d)
Is the Future of AI Drug Discovery Hybrid?
(5d)
Drug Channels
Why GoodRx Is Built for the AI-Driven Patient Journey
(13h)
The Spinoff: How Biosimilars Are Becoming Wholesalers' Next Hit Show
(3d)
Keep Your Patient Program at the Forefront of Innovation at Patient Pathways: The Copay and Patient Services Congress
(4d)
Fixing the Front Door Isn’t the Same as Fixing Time to Therapy
(1w)
Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(1w)
European Biotechnology Magazine
Bavarian Nordic names new CEO; Abivax and ProQR add key leaders
(15h)
Roche signs two deals worth about $3.5B in one day
(16h)
Nine pharma companies urge Europe to invest more in medicines
(1d)
Kasvu raises €30M for depression drug targeting TrkB
(1d)
Boehringer pays up to $250M to expand Variant Bio’s pact into heart disease
(1d)
Drug Hunter
QTX3034
(9h)
DAC 44
(1d)
Can Antibody Conjugation Offer a Path Forward for Genentech’s SMARCA2 Degraders?
(1d)
INCB161734
(2d)
ritonavir
(3d)
Labiotech.EU
Theialife’s race to bring a childhood myopia treatment to market
(15h)
“An open and collaborative culture”: what makes Sweden attractive for life sciences
(2d)
AstraZeneca’s pipeline strategy: building the next wave of growth
(3d)
How to navigate the IND process and shorten DNA-to-IND timelines to 6 months
(3d)
What can GLP-1s do beside treat diabetes and obesity?
(4d)
Bio IT World
A Field in Transition: T Cell Engagers
(1d)
Elsevier, LG AI Research Integrate Chemistry-Specific AI Vision
(2d)
Apheris Announced the Results of their Federated Learning Co-Folding Initiative—Now Four Big Pharma Are Betting Bigger
(3d)
AI Can Help Find New Uses for Old Drugs; Advancing Them to Patients Is the Hard Part
(1w)
A 1970s Lipid-Lowering Compound May Offer a New Approach to Obesity
(1w)
GEN News
Thar Process Partners with ExtrateX to Bring Prep to Process-Scale SFC to Europe
(5h)
How Bladder Cells Fight Hidden E. coli: New Insights Into Recurrent UTIs
(5h)
Stroke Remodels Tumor Microenvironment to Promote Glioma Growth
(7h)
New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages
(14h)
APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s
(1d)
Cure Today
How Paxalisib Is Being Studied in Treatment-Resistant Breast Cancer
(3h)
Three August Blood Cancer Approvals and What They Mean for Care
(4h)
Walking Linked to 26% Lower Odds of Severe Fatigue After Colorectal Cancer
(6h)
How to Preserve Your Own Hair During Cancer Treatment
(7h)
Could a Genomic Test Spare You Extra Years of Hormone Therapy?
(9h)
Contract Pharma
Contract Pharma 2026 Conference Concludes with Risk Management Forum
(3h)
Reducing Product Loss in Sterile Manufacturing
(8h)
SK pharmteco Launches Catalyst Kit
(8h)
Recipharm, CanVirex Partner on Oncolytic Virus Manufacturing
(8h)
The Friday Brief for September 25, 2026: Live from Contract Pharma 2026
(9h)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1w)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1w)
Zerion partner files first EU application for Dispersome‑enabled product
(1w)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1w)
Study highlights advance in influenza protection for older adults
(1w)
Medcity News
Report: High Drug Costs Are Creating Hidden Burden for Physicians
(1h)
Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut
(4h)
AI Goes All In To Support Nursing Teams: Ambient Charting is Just the Start
(10h)
UHC, Cigna and Centene Sign On to New National Shared Credentialing Program
(1d)
Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact
(1d)
Chemical & Engineering News
BASF is in talks to buy Evonik
(4h)
At Climate Week, technology is still a solution to climate change
(6h)
Policy Watch: HHS and EPA move to coordinate on glyphosate review
(8h)
How wildfire smoke put Bordeaux’s wine at risk
(9h)
C&EN weekly chemistry news quiz, Sept. 25
(9h)
The Pharma Letter
Zenbexus doubles MRD-negative complete response rate in pivotal myeloma trial
(8h)
Nanexa soars on Novo deal for injection technology
(8h)
China expands role in manufacturing new FDA-approved drugs - thepharmaletter.com
(9h)
Merck’s Ogsiveo greenlighted by NICE - thepharmaletter.com
(9h)
Carvykti delivers five-year treatment-free remission in half of early-line myeloma patients - thepharmaletter.com
(9h)
Targeted Oncology
Durvalumab-EV Perioperative Regimen Receives FDA Priority Review in MIBC
(3h)
Rethinking Transplant Eligibility in Multiple Myeloma in the MRD Era
(5h)
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
(6h)
Etentamig Shows Success With Focus on Tolerability, Administration in Relapsed Myeloma
(7h)
Etentamig Improves Response, PFS in Triple-Class Exposed Myeloma
(8h)
MedWatch
GSK reprimanded for lack of transparency in vaccine campaign case
(14h)
Low expectations could turn into an advantage for Novo in 2027, says Saxo strategist
(14h)
Nanexa deal shows Novo's appetite for new growth avenues, analyst says
(14h)
Hemab Therapeutics reshuffles board
(15h)
MSD’s eye drug meets primary endpoint in trial
(15h)
In The Pipeline
AI Help for Biological or Chemical Weapons
(1d)
As Close to Carbyne As We're Probably Going to Get
(2d)
tRNA Therapy
(3d)
Yet Another Attempt to Strangle Scientific Funding
(4d)
Safety Warning: Carborane Mixtures
(1w)
Pharmaphorum
EU clears first drug therapy for rare disease cALD
(11h)
FDA starts speedy review of Imfinzi in bladder cancer
(12h)
FDA nominee Overton dodges questions on Trump influence
(13h)
Wnt drug gives MSD first eye disease win after EyeBio deal
(15h)
Australia starts probe into AI infiltration of Medicare
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(3mo)
Therapy enables 89% survival rate in myeloma patients
(3mo)
Ulcerative colitis treatment shows best-in-class potential
(3mo)
HIT Consultant
Basalt Health Raises $20M to Scale Post-Acute AI Transition Platform Across 111 Markets
(1d)
CancerIQ Expands Native Epic Integrations to Automate Cancer Screening and Survivorship Across 275 Clinics
(1d)
Everlywell Appoints Chief Commercial and Product Officers to Expand Payer Diagnostic Care Platforms
(1d)
Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation
(1d)
Oracle Health Partners with ID.me to Embed Reusable Digital Identity Across Patient Portals and EPCS
(1d)
Insights: Pink Sheet
Three Topics Dominated US FDA Commissioner Nominee Overton’s Senate Hearing
(1h)
Industry Pushes US FDA To Define ‘Highly Persuasive’ Single-Trial Bar
(2h)
Rosa Sherafat Takes Over US FDA Gene Therapy Clinical Review Office
(2h)
Another China Biotech Warning: Analysis Shows China Passes US In Oncology Approvals
(6h)
Pink Sheet Podcast: Lessons From US FDA Commissioner Nominee Heidi Overton’s Confirmation Hearing
(7h)
BioXconomy
Sanofi’s regulatory leader breaks down ICH’s regulatory submission overhaul
(5h)
Avoiding the foul ball: Manufacturing siRNAs to improve patient adherence
(7h)
China's InnoCare lands up to $3.35bn Lilly deal
(8h)
How AI is streamlining patient support behind the scenes
(10h)
How AI is streamlining patient support behind the scenes
(10h)
BioCentury
Network Bio: Building disease-specific AI models with biobank data
(23h)
Enveda’s latest megaround puts $311M behind AI push: Venture Report
(23h)
Overton vows speed, deference to staff reviews, if confirmed to lead FDA
(1d)
How Europe’s VCs are chasing NewCo deals in China
(2d)
Amicus vet Campbell to succeed Dube as Travere CEO
(2d)
SCRIP
Mirum’s Atebrioz, First Oral Approved For FOP, To Face Regeneron’s Pasatru
(1h)
Merck’s Withdrawal Of Recarbrio Takes It Off The Antibiotic Board
(2h)
Finance Watch: Big Money Keeps Flowing To AI-Enabled Drug Discovery And Development
(6h)
Mid-Sized Pharma And Lilly Setting M&A Pace In 2026
(7h)
The Eight Potential Immunological Blockbusters Coming To Market In 2027
(10h)